Biomarker ID | 1414 |
PMID | 24741114 |
Year | 2014 |
Biomarker | POSTN; ASPN; LAMB2; SERPH; CSPG2; ENTP1; SE1L1; ITAV; FOLH1; STIM1; PTK7; ICOSL; SPP2A; CD276; KLK3; ZA2G; FBN1; CD38; CNTP2; AMPN; FAM3B; RNT2; NAAA; PPAP; GSLG1; TSN1; DPP4; ST14; |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Agressive PCa; Downregulated in Agressive PCa: [] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Agressive Vs Non Agressive PCa |
Type of Biomarker | Prognostic |
Cohort | 25 patients with Metastatic Prostate Cancer (PCa); 10 normal samples; 24 Non Agressive PCa patients and 16 agressive PCa patients were included in the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | NA |
Method Used | SWATH Mass Spectrometry |
Clinical | No |
Remarks | Agressive PCa: Patients with Gleason scores of 8 or 9 and Gleason scores of 7 from patients who either died of cancer metastasis within 6 years of surgery or were positive for metastatic tumor at the time of surgery |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |